These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11054568)

  • 1. Puromycin resistance (pac) gene as a selectable marker in vaccinia virus.
    Sánchez-Puig JM; Blasco R
    Gene; 2000 Oct; 257(1):57-65. PubMed ID: 11054568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hygromycin-resistance-encoding gene as a selection marker for vaccinia virus recombinants.
    Zhou J; Crawford L; Sun XY; Frazer IH
    Gene; 1991 Nov; 107(2):307-12. PubMed ID: 1660832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient selection during vaccinia virus recombination with insertion vectors without selectable markers.
    Kurilla MG
    Biotechniques; 1997 May; 22(5):906-10. PubMed ID: 9149873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BiZyme: a novel fusion protein-mediating selection of vaccinia virus recombinants by fluorescence and antibiotic resistance.
    Hansen SG; Cope TA; Hruby DE
    Biotechniques; 2002 May; 32(5):1178, 1180, 1182-7. PubMed ID: 12019792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defective vaccinia virus as a biologically safe tool for the overproduction of recombinant human secretory proteins.
    Himly M; Pfleiderer M; Holzer G; Fischer U; Hannak E; Falkner FG; Dorner F
    Protein Expr Purif; 1998 Dec; 14(3):317-26. PubMed ID: 9882565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neomycin resistance as a dominant selectable marker for selection and isolation of vaccinia virus recombinants.
    Franke CA; Rice CM; Strauss JH; Hruby DE
    Mol Cell Biol; 1985 Aug; 5(8):1918-24. PubMed ID: 3018537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for all-at-once and stepwise selection of cells with multiple genetic manipulations.
    Horikawa M; Sabe H; Onodera Y
    Biochem Biophys Res Commun; 2021 Dec; 582():93-99. PubMed ID: 34695756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Puromycin-N-acetyltransferase as a selectable marker for use in Plasmodium falciparum.
    de Koning-Ward TF; Waters AP; Crabb BS
    Mol Biochem Parasitol; 2001 Oct; 117(2):155-60. PubMed ID: 11606225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of bovine leukaemia virus envelope gene by recombinant vaccinia viruses.
    Kumar S; Andrew ME; Boyle DB; Brandon RB; Lavin MF; Daniel RC
    Virus Res; 1990 Oct; 17(2):131-42. PubMed ID: 1963249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCR-based method for the introduction of mutations in genes cloned and expressed in vaccinia virus.
    Lorenzo MM; Blasco R
    Biotechniques; 1998 Feb; 24(2):308-13. PubMed ID: 9494734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation of a vaccine strain of vaccinia virus via inactivation of interferon viroceptor.
    Dénes B; Gridley DS; Fodor N; Takátsy Z; Timiryasova TM; Fodor I
    J Gene Med; 2006 Jul; 8(7):814-23. PubMed ID: 16634110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function.
    Jenne L; Hauser C; Arrighi JF; Saurat JH; Hügin AW
    Gene Ther; 2000 Sep; 7(18):1575-83. PubMed ID: 11021596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A recombinant vaccinia virus encoding inducible nitric oxide synthase is attenuated in vivo.
    Rolph MS; Cowden WB; Medveczky CJ; Ramshaw IA
    J Virol; 1996 Nov; 70(11):7678-85. PubMed ID: 8892888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bifunctional protein conferring enhanced green fluorescence and puromycin resistance.
    Abbate J; Lacayo JC; Prichard M; Pari G; McVoy MA
    Biotechniques; 2001 Aug; 31(2):336-40. PubMed ID: 11515370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An efficient method for generating poxvirus recombinants in the absence of selection.
    Rice AD; Gray SA; Li Y; Damon I; Moyer RW
    Viruses; 2011 Mar; 3(3):217-32. PubMed ID: 21494427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of vaccinia virus DNA replication by inducible expression of nitric oxide synthase.
    Mĕlková Z; Esteban M
    J Immunol; 1995 Dec; 155(12):5711-8. PubMed ID: 7499858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient transformation of mammalian cells with constructs containing a puromycin-resistance marker.
    de la Luna S; Soria I; Pulido D; Ortín J; Jiménez A
    Gene; 1988; 62(1):121-6. PubMed ID: 3371661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A general method for the construction of recombinant vaccinia viruses expressing multiple foreign genes.
    Coupar BE; Andrew ME; Boyle DB
    Gene; 1988 Aug; 68(1):1-10. PubMed ID: 2851485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fusion gene vectors allowing for simultaneous drug selection, cell labeling, and reporter assay in vitro and in vivo.
    Zhao H; Hong N; Lu W; Zeng H; Song J; Hong Y
    Anal Chem; 2012 Jan; 84(2):987-93. PubMed ID: 22081858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response.
    Coupar BE; Andrew ME; Both GW; Boyle DB
    Eur J Immunol; 1986 Dec; 16(12):1479-87. PubMed ID: 3493144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.